Were James Mulay’s CG Oncology (CGON) share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2026. Such pre-arranged plans schedule trades in advance, reducing the significance of short-term market timing decisions.

CG Oncology director sells shares, exercises options

CG Oncology, Inc. director James Mulay reported an exercise-and-sell transaction in company stock.

Accepted by SEC EDGAR 06/16/2026 - 05:07 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CG Oncology, Inc. director James Mulay reported an exercise-and-sell transaction in company stock. He exercised options for a total of 1,964 shares of Common Stock at strike prices of $12.59 and $3.72 per share, then sold 1,964 shares in open-market trades at $60.12 per share.

The options exercised were Director Stock Options with expiration dates in 2033. A footnote states the sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026, indicating these dispositions were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,964 shares ($99K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Mulay James

Role Director

Sold 1,964 shs ($118K)

Approx. gross sale proceeds $118K

Approx. exercise cost $19K

Approx. pre-tax spread $99K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy)	654	$0.00	$0.00
Exercise	Director Stock Option (right to buy)	1,310	$0.00	$0.00
Exercise	Common Stock	654	$3.72	$2K
Sale	Common Stock	654	$60.12	$39K
Exercise	Common Stock	1,310	$12.59	$16K
Sale	Common Stock	1,310	$60.12	$79K

Holdings After Transaction: Director Stock Option (right to buy) — 2,620 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (3)

F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
F2. The stock option vested in 36 substantially equal monthly installments beginning on July 14, 2023.
F3. The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.

Key Figures

Shares sold: 1,964 shares Sale price: $60.12 per share Options exercised: 1,964 shares +5 more

8 metrics

Shares sold 1,964 shares Common Stock open-market sales on June 15, 2026

Sale price $60.12 per share Common Stock sale transactions

Options exercised 1,964 shares Director Stock Option exercises of Common Stock

Option strike price 1 $12.59 per share Director Stock Option with 1,310 underlying shares

Option strike price 2 $3.72 per share Director Stock Option with 654 underlying shares

Rule 10b5-1 plan adoption date March 27, 2026 Covers the reported sales

Option expiration 1 December 12, 2033 Director Stock Option with $12.59 strike

Option expiration 2 June 13, 2033 Director Stock Option with $3.72 strike

Key Terms

Rule 10b5-1 trading plan, Director Stock Option (right to buy), Exercise or conversion of derivative security, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)" with underlying Common Stock shares."

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security" for option exercises."

open-market sale financial

"transaction_action: "open-market sale" at $60.1200 per share of Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CGON director James Mulay report on this Form 4?

James Mulay reported exercising options and selling CG Oncology, Inc. (CGON) Common Stock. He exercised options for 1,964 shares, then sold 1,964 shares in open-market transactions, reflecting an exercise-and-sell pattern rather than a new open-market share purchase.

How many CG Oncology (CGON) shares did James Mulay sell and at what price?

James Mulay sold 1,964 shares of CG Oncology, Inc. Common Stock. The reported open-market sale price was $60.12 per share, recorded across two sale transactions on the same date, matching the number of shares acquired through option exercises.

What option strike prices did James Mulay exercise for his CGON shares?

He exercised director stock options covering 1,964 CG Oncology, Inc. shares at strike prices of $12.59 and $3.72 per share. These exercises converted derivative awards into Common Stock before the corresponding open-market sales reported in the filing.

What do the option expiration dates indicate in James Mulay’s CGON Form 4?

The director stock options had expiration dates in 2033, specifically December 12, 2033 and June 13, 2033. Exercising these options converts them into shares before expiration, which were then sold in the open market as reflected in the non-derivative transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulay James

(Last)

(First)

(Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS

TEXAS

75247

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		M		654	A	$3.72	654	D
Common Stock	06/15/2026		S⁽¹⁾		654	D	$60.12	0	D
Common Stock	06/15/2026		M		1,310	A	$12.59	1,310	D
Common Stock	06/15/2026		S⁽¹⁾		1,310	D	$60.12	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$3.72	06/15/2026		M			654	⁽²⁾	06/13/2033	Common Stock	654	$0	0	D
Director Stock Option (right to buy)	$12.59	06/15/2026		M			1,310	⁽³⁾	12/12/2033	Common Stock	1,310	$0	2,620	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

2. The stock option vested in 36 substantially equal monthly installments beginning on July 14, 2023.

3. The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.

	/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR